Figure 1A
Five patients died in the RDAVR group, exclusively from
non-cardiovascular causes. In the TAVR group, 13 patients died, mainly
from a cardiovascular causes including CHF (n=6), myocardial infarction
(n=1), sudden cardiac death (n=1) and infective endocarditis (n=1). By
propensity score matching analysis, there was a trend in favor of RDAVR
concerning all-cause mortality without reaching statistical significance
(HR = 0.40[95%CI:0.12,1.14], p=0.08). Figure 1B
Five patients were hospitalized in the RDAVR group, exclusively due to
congestive heart failure (CHF). In the TAVR, 10 patients were
hospitalized, mainly due to CHF (80%). The rate of re-hospitalization
related to the procedure, the valve, or heart failure at two-years FU
was 39.58% in the RDAVR group and 60.42% in the TAVR group. By
propensity score matching analysis, there was a significant difference
between both groups in favor of RDAVR (HR=0.56[95%CI 0.32,1.0],
p=0.04). Figure 1C
No disabling stroke occurred in the RDAVR group and one (2.08%)
occurred in TAVR group.